论文部分内容阅读
目的观察左卡尼汀治疗不稳定型心绞痛的临床疗效及安全性。方法125例符合不与标准的患者,通过心肌标记物测定排除非ST段抬高型心肌梗死,随机分为治疗组65例和对照组60例。治疗组在与对照组常规治疗相同的基础上加用左卡尼汀2.0g静脉滴注,1次/d,共14d。对照组应用低分子肝素钙、阿司匹林及调脂治疗,根据病情给予硝酸酯类、β受体阻滞剂、钙拮抗剂、血管紧张素抑制剂等药物治疗。观察2组心电图改变、症状控制情况、主要终点事件及不良反应发生情况。结果治疗组与对照组心电图缺血性改变、症状控制情况、1个月内心肌梗死及心脏猝死等主要终点事件2组无明显差异,无严重不良反应。结论左卡尼汀治疗不稳定型心绞痛安全有效。
Objective To observe the clinical efficacy and safety of levocarnitine in the treatment of unstable angina pectoris. Methods A total of 125 patients who did not meet the criteria were excluded from the study. Myocardial infarction markers were excluded from the study and were randomly divided into treatment group (n = 65) and control group (n = 60). The treatment group and the control group on the basis of conventional treatment plus levocarnitine 2.0g intravenous infusion, 1 / d, a total of 14d. Control group of low molecular weight heparin, aspirin and lipid-lowering treatment, according to the condition given nitrates, β-blockers, calcium antagonists, angiotensin inhibitors and other drugs. Two groups of ECG changes, symptom control, main endpoints and adverse reactions were observed. Results There was no significant difference between the two groups in the main endpoint events such as ischemic changes of electrocardiogram, symptom control, myocardial infarction and sudden cardiac death in the treatment group and the control group, with no serious adverse reactions. Conclusion L-carnitine is safe and effective in the treatment of unstable angina pectoris.